anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This disclosure provides systems and methods for facilitating communication of health information. A system can include a request management module to receive, from a source endpoint, an electronic query. The query can be formatted according to a first communications protocol and can include at least one request parameter. A destination identifier module can determine a destination endpoint and a second destination endpoint. A translation module can translate the electronic query from the first communications protocol to a second communications protocol associated with the destination endpoint to generate a translated query. The translation module can also translate the electronic query from the first communications protocol to a third communications protocol associated with the second destination endpoint to generate a second translated query. The request management module can transmit the translated query and the second translated query to the destination endpoint and the second destination endpoint, respectively.
Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid haemorrhage (aSAH) is a singular pathological entity necessitating early diagnostic approaches and both prophylactic and curative interventions. This retrospective before-after study investigates the effects of a management strategy integrating perfusion computed tomography (CTP), vigilant clinical monitoring and standardized systemic administration of milrinone on the occurrence of delayed cerebral infarction (DCIn). The "before" period included 277 patients, and the "after" one 453. There was a higher prevalence of Modified Fisher score III/IV and more frequent diagnosis of vasospasm in the "after" period. Conversely, the occurrence of DCIn was reduced with the "after" management strategy (adjusted OR 0.48, 95% CI [0.26; 0.84]). Notably, delayed ischemic neurologic deficits were less prevalent at the time of vasospasm diagnosis (24 vs 11%, p = 0.001  ), suggesting that CTP facilitated early detection. In patients diagnosed with vasospasm, intravenous milrinone was more frequently administered (80 vs 54%, p < 0.001  ) and associated with superior hemodynamics. The present study from a large cohort of aSAH patients suggests, for one part, the interest of CTP in early diagnosis of vasospasm and DCI, and for the other the efficacy of CT perfusion-guided systemic administration of milrinone in both preventing and treating DCIn.
Patients randomized to the control group (QFR-guided group) will undergo invasive coronary angiography (ICA) in the catheterization lab, and QFR will be calculated using the ICA images. The researchers will interpret and analyze the clinical outcomes based on QFR results. If QFR is ≤0.8 and the lesion is suitable for intervention, the patient will undergo percutaneous coronary intervention (PCI) treatment. If QFR is \>0.8, the patient will be recommended for medical treatment alone.
This study aimed to evaluate (co)variance components and heritability of pre-weaning body weight traits and the Kleiber ratio in Akkaraman sheep. Data collected between 2018 and 2023 from Çankırı province, Türkiye, formed the basis of this research. The considered traits were birth weight (BW), weaning weight (WW), average pre-weaning daily weight gain (ADWG), and Kleiber ratio (KR). Utilizing animal mixed models and the average information restricted maximum likelihood (AI-REML) procedure, genetic parameters were estimated. Direct heritability estimates were 0.30 ± 0.02, 0.23 ± 0.02, 0.23 ± 0.02, and 0.28 ± 0.03 for BW, WW, ADWG, and KR, respectively. Maternal genetic heritabilities were 0.03 for WW and 0.02 for WW, ADWG, and KR. Direct genetic correlations among pre-weaning growth traits were negative for BW-WW and BW-ADWG and positive for WW-ADWG at -0.05, -0.23, and 0.98, respectively. The moderate direct heritability estimate suggests the presence of genetic variability in the Akkaraman sheep breed, indicating potential genetic progress through selective breeding. Despite the low maternal permanent environmental effects, the significant impact of maternal care on lamb growth in this breed underscores the importance of considering both direct and maternal effects in the genetic evaluation of early growth traits. The observed negative genetic correlations among birth weight, weaning weight, and daily live weight gain until weaning emphasize the need for careful consideration in selection programs for the Akkaraman breed.
The primary aim of this prospective, international audit of practice is to identify risk factors for failure of epidural blood patch (EBP) in the Obstetric population after accidental dural puncture (ADP) with an epidural needle. Other aims are to describe the epidemiology, management principles, side effects and complications of ADP and longer-term effects of ADP on patients undergoing Obstetric anaesthesia and analgesia. Expectation is that this audit of practice will provide important information in understanding the reasons for failure of EBP and subsequently to better manage parturients affected by this debilitating complication.

Postdural puncture headache (PDPH) is the most common serious complication of accidental dural puncture (ADP), and feared by every Anaesthesiologist. It is associated with significant peri-partum maternal distress, and poor bonding with the baby, which in turn leads to physical disability for the mother and psychological and social implications for the whole family. It is estimated that about 10,000 parturients in Europe may have an accidental dural puncture (ADP) each year. Attitudes and practices in the management of ADP are based on small studies, and sometimes driven by experience rather than evidence. Although several methods have been described in the literature to treat PDPH, one common method used is an epidural blood patch (EBP). This is believed to be successful in about 60-80% of parturients on the first attempt, but results from most studies are based on a small numbers of patients. The reasons and predisposing factors for success and failure of different management strategies, specifically EBP, therefore needs to be investigated and described. Large observational studies on post-dural puncture headache in the Obstetric population are singularly absent from the literature.
Truth-telling and life-sustaining treatment decisions are important elements of the quality of patients' care at the end of life. As the primary caregivers of patients at the end of life in intensive care units (ICUs), ICU nurses play an important role in patient decision making and hospice care. This study aimed to investigate and analyze ICU nurses' attitudes toward truth-telling, attitudes toward end-of-life life-sustaining treatment, and end-of-life decision-making behavioral intentions. One hundred twenty-two ICU nurses participated in this cross-sectional survey. Data were collected using a validated questionnaire. The results showed that ICU nurses' attitudes toward telling patients the truth and end-of-life life-sustaining treatment were both positive, but further improvement is needed. Nurses have a higher willingness to make palliative care decisions for patients at the end of life and to help patients achieve a good death. The truth-telling attitude, the life-sustaining treatment attitude, and whether they knew that cardiopulmonary resuscitation could be legally forgone at the end of life were factors influencing ICU nurses' behavioral intention toward decision making for patients at the end of life (all P s < .05). We conclude that nurses' participation in truth-telling and end-of-life decision making should be promoted, and timely hospice care should be provided to patients to help them achieve a good death.
PURPOSE:To obtain the subject improving agent giving such excellent activity as to decrease low-specific gravity lipoprotein level and increase high-specific gravity lipoprotein level, containing a phosphoric diester compound of ascorbic acid and tocopherol or a salt thereof. CONSTITUTION:This lipid metabolism improving agent contains a phosphoric diester compound of the formula (R1 and R2 each are H or methyl) or a pharmacologically permissible salt thereof. The compound of the formula is e.g. phosphoric diester pottasium salt of L-ascorbic acid and DL-alpha-tocopherol, being extremely low toxic and excellent in safety. The improving agent has ability to lower respective levels of neutral lipid, free fatty acid, total cholesterol, ester-type cholesterol, free cholesterol, total lipid and lipid peroxide in the blood, raise high-specific gravity lipoprotein fraction level and lower low- specific gravity lipoprotein and ultra low-specific gravity lipoprotein fraction levels. Therefore, this improving agent is effective for various arteriosclerotic diseases such as cardiac infarction, stenocardia, cerebral infarction and cerebral arteriosclerosis, nephtosis, hypertension, diabetes, etc.
FIELD: medicine; pharmaceuticals.SUBSTANCE: what is offered is a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, losing weight, reducing blood sugar, reducing lipids, inhibiting appetite in a subject, reducing the total serum cholesterol level and/or reducing the triglyceride content in the liver, its version, the composition and use of said compositions. Said pharmaceutical composition contains a pharmaceutically effective amount of a GLP-1 receptor agonist and a glucagon receptor agonist. GLP-1 receptor agonist and the glucagon receptor agonist each independently form a conjugate with a hydrophilic polymer, a molar ratio of the conjugate, including a GLP-1 receptor agonist, to a conjugate comprising a glucagon receptor agonist ranges from 1:1 to 1:15. In the above composition, the GLP-1 receptor agonist is selected from exendin-4, exendin-3 and GLP-1, and the glucagon receptor agonist is glucagon and the hydrophilic polymer is polyethylene glycol. Variant of the pharmaceutical composition comprises an agent selected from a group consisting of: a combination of PB-721 and PB-119, a combination of PB-722 and PB-119 and a combination of PB-708 and PB-120, where PB-721 is mPEG-23KD-ppMAL-PB-740, where PB-740 has an amino acid sequence SEQ ID NO: 5; PB-722 is mPEG-23KD-ppMAL-PB-741, where PB-741 has the amino acid sequence SEQ ID NO: 6, in which the "-CO-NH" side chain of glutamine in 24 position is modified in "-CO-NH-CHCH-SH"; PB-119 is mPEG-23KD-ppMAL-PB-105, where PB-105 has the amino acid sequence SEQ ID NO: 1; PB-120 is mPEG-25KD-ppMAL-PB-105, where PB-105 has the amino acid sequence SEQ ID NO: 1; and PB-708 is mPEG-25KD-ppMAL-PB-703, where PB-703 has the amino acid sequence SEQ ID NO: 4. What is also presented is a kit for preventing or treating non-alcoholic fatty liver disease, losing weight, reducing blood sugar, lowering lipids, inhibiting appetite in the individual, reducing total serum cholesterol and/or reducing triglycerides in the liver, comprising the composition.EFFECT: composition and variant thereof can be used for preparing a drug for preventing or treating non-alcoholic fatty liver disease, losing weight, reducing lipids and/or reducing blood sugar, as well as for preparing a drug for suppressing appetite in a subject, reducing the level of total cholesterol in the serum and/or reducing the content of triglycerides in the liver.11 cl, 40 dwg, 3 tbl, 21 ex
A system, method, and computer program product for athlete monitoring through a user interface is provided. The method includes receiving a first and second user input defining a current status of a user associated with a first and second readiness characteristic, respectively, prior to a training session or a match. From the first and second user input a readiness level for the user is determined. The method further includes receiving a third user input defining an exertion level of the user during a previous training session or a previous match, wherein the exertion level is associated with the perceived exertion level of the user during the training session or the previous match. Using the exertion level and duration of the session, a training load level of the previous training session or previous match is determined. The method further includes causing display of the readiness level for the user and the training load.
Left bundle branch pacing (LBBP) has been subject to increasing interest over the last few years due to its capacity for physiological conduction and its advantages compared to His bundle pacing. His bundle pacing has certain limitations, such as a small pacing area for the His bundle, a high threshold that leads to battery depletion, a low R-wave amplitude that may result in atrial or His oversensing, and ventricular signal undersensing. In this case series, four patients (two female and two male) aged 62.2 ± 8.4 years old with symptomatic sick sinus disease and no scar tissue in the interventricular septum underwent LBBP. All LBBPs were done with standard LBBP using a lumenless SelectSecure 3830 lead (Medtronic®, Minneapolis, USA) with a fixed helix. The lead parameters showed a good R-wave amplitudes (13 ± 7.4 mV) and a low threshold  (0.77 ± 0.17 V @ 0.4 ms). All patients were discharged on the next day. During follow-up period of 13.3 ± 12.9 months, all patients were well and no complications were noted. In conclusion, LBBP may be as an alternative of novel conduction pacing techniques and can be done relatively easy and safe, even with limited experience center.
PURPOSE:To eliminate the irritability to a living body by obtaining biocompatibility and adjusting the pH of a kneaded mixture to the vicinity of neutrality by using an aqueous solution of at least one kind of a salt selected from a group consisting of diammonium phosphate, ammonium oxalate, ammonium acetate and sodium hydrogen tartarate as a curing liquid. CONSTITUTION:In a composition consisting of a powder, which consists of 100pts.wt. of an alpha-tricalcium phosphate powder and 5-30pts.wt. of a iodoform powder, and a curing liquid, an aqueous solution of a salt constituting said curable composition contains 10-40wt.% of diammonium phosphate, 3-5wt.% of ammonium oxalate, 20-60wt.% of ammonium acetate or 3-5wt.% of sodium hydrogen tartarate. When the concn. of the aqueous solution is lower than this range, the curability and workability of the curable composition become inferior and, when said concn. is higher than said range, the solubility of a kneaded cured substance becomes large. As the curing liquid, an aqueous solution of polyalkylene glycol (concentration, 5-15wt.%) can be together used in order to improve kneading properties.
Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
BACKGROUND: Immune thrombocytopenic purpura (ITP) is a disease characterized by a decrease in platelet count, which can be triggered by various factors, including viral infections and vaccination. With the widespread vaccination against COVID-19, concerns have arisen regarding a possible link between the vaccine and the exacerbation of ITP. This study aims to comprehensively evaluate the impact of COVID-19 vaccination on ITP patients, including associated risks and outcomes.
METHODS: A comprehensive search will be conducted in multiple electronic databases (including PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, Wan Fang, VIP, and CBM) to identify relevant studies. This study will include randomized controlled trials, cohort studies, case-control studies, and case series evaluating the impact of COVID-19 vaccination on ITP patients. The primary outcome measure is the change in platelet count, while secondary outcome measures include the occurrence of thromboembolic events, bleeding complications, ITP recurrence rate, impact of ITP exacerbation, and adverse events. Data will be summarized and analyzed using Review Manager Software (RevMan) V.5.4. In addition, subgroup analyses will be performed to explore potential sources of heterogeneity.
RESULTS: It is anticipated that different types of COVID-19 vaccines may have varying impacts on ITP patients, leading to potential differences in outcomes. This study aims to comprehensively evaluate the potential impact of COVID-19 vaccination on ITP patients and provide reference for clinical decision-making.
CONCLUSIONS: The results of this systematic review and meta-analysis will provide crucial information on COVID-19 vaccination for ITP patients and clinicians, contributing to guiding vaccination decisions and monitoring potential impacts after vaccination.
Autism spectrum disorder (ASD) is a common highly heritable neurodevelopmental disorder with high genetic and clinical heterogeneity. Due to its high prevalence, long-term impairment, unclear etiologies, and a lack of effective detection, prevention and biological treatment for this disorder, this catastrophic disorder has been prioritized for molecular genetic and brain research. The main PI Gau has established a cohort of more than 900 ASD probands and their families with clinical, neuropsychological, image, and genetic data. With the advance in digit health, this integrated project aims to develop and potentially commercialize an objective, automated assessment system for early diagnosis of ASD based on the clinical, behavioral, neuropsychological, neuroimaging, genetic (whole exome sequencing, WES), metabolomics, and microbiomics data of probands with ASD and typically developing controls(TDC) without ASD

This 3-year, 5 subprojects (SP) project is based on an existing big cohort of \> 900 ASD probands and their families with high-quality genetic data, clinical diagnoses, symptoms, psychopathology, social functions, neuropsychological functions (n= 600 for CPT, 300 for CANTAB), and structural and functional images (n=196), data. Due to a limited budget, SP1 will only select 360 ASD (ages 4-25 years old) and 90 TDC for this integrated project. SP1 will check the quality and presence of the data followed by recollecting DNAs of 100 ASD, MRI data of 205 ASD (360-196=164, 164/0.8(successful rate)=205), and CANTAB of 60 ASD to have a complete dataset of clinical/phenotype/neurocognition/image measures. SP1 will prepare DNAs for SP2's WES analyses; and will collect serum and stool of 360 ASD and 90 TDC and provide these samples to SP3 and SP4 for metabolomics and microbiomics analyses, respectively. All the data collected and results generated from SP1-4 will be saved and managed in the ASD bank (SP1, main PI) and analyzed by SP5 using AI machine learning to develop the precise objective automatic assessment platform for ASD. The topics of the five subprojects:

Subproject 1. Establishing the standard procedure for data collection and clinical-biological bank of autism spectrum disorder including clinical, behavioral, cognitive, neuroimaging, genetic, and biological data Subproject 2. Deciphering genetic cause in autistic spectrum disorder using whole exome sequencing Subproject 3. Metabolomics investigation of Autism Spectrum Disorder Subproject 4. Intestinal microbiota and disease outcome in children with autism spectrum disorder Subproject 5. A computerized assessment system from genome, gut-brain, and metabolic mechanisms
High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
A G4P4 woman in her 30s with a type II vesicouterine fistula, as defined by the Jozwik classification system, presented with symptoms of menouria, vaginal menses and urinary incontinence 8 years after caesarean delivery, the time of probable origination of the fistula tract. Transvaginal ultrasound identified a fistula tract communicating between the bladder and uterus, a rare finding that many years remote from caesarean delivery. Traditional surgical technique includes laparoscopic, abdominal and endoscopic methods of repair, sometimes using a transvesical approach. Transvesical repair can be associated with subsequent inpatient hospital stays and prolonged catheterisation. Our technique proposes a transvaginal surgical approach as an outpatient procedure with decreased operating time (40 min), postoperative pain and catheterisation requirement. It is the authors' belief that a transvaginal approach is less invasive and allows for better preservation of the uterus for future pregnancies and vaginal deliveries, as desired by the patient.
### Verapamil Component

An 18-month toxicity study in rats, at a low multiple (6 fold) of the maximum recommended human dose, and not the maximum tolerated dose, did not suggest a tumorigenic potential. There was no evidence of a carcinogenic potential of verapamil administered in the diet of rats for two years at doses of 10, 35, and 120 mg/kg per day or approximately 1x, 3.5x, and 12x, respectively, the maximum recommended human daily dose (480 mg per day or 9.6 mg/kg/day).

Verapamil was not mutagenic in the Ames test in 5 test strains at 3 mg per plate, with or without metabolic activation. 

Studies in female rats at daily dietary doses up to 5.5 times (55 mg/kg/day) the maximum recommended human dose did not show impaired fertility. Effects on male fertility have not been determined.

Long-term studies were conducted with oral trandolapril administered by gavage to mice (78 weeks) and rats (104 and 106 weeks). No evidence of carcinogenic potential was seen in mice dosed up to 25 mg/kg/day (85 mg/m2/day) or rats dosed up to 8 mg/kg/day (60 mg/m2/day). These doses are 313 and 32 times (mice), and 100 and 23 times (rats) the maximum recommended human daily dose (MRHDD) of 4 mg based on body-weight and body-surface-area, respectively assuming a 50 kg individual. The genotoxic potential of trandolapril was evaluated in the microbial mutagenicity (Ames) test, the point mutation and chromosome aberration assays in Chinese hamster V79 cells, and the micronucleus test in mice. There was no evidence of mutagenic or clastogenic potential in these in vitro and in vivo assays.

Reproduction studies in rats did not show any impairment of fertility at doses up to 100 mg/kg/day (710 mg/m2/day) of trandolapril, or 1250 and 260 times the MRHDD on the basis of body-weight and body-surface-area, respectively.